Latest filing published 12 May 2026 for Novo Nordisk A/S, €1,969. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
member/Executive/Associated Person discloses dealings in 2 companies, chiefly Novo Nordisk A/S and of the Board. The record holds 114 filings, for trades running from 31 October 2016 to 7 May 2026.
In open-market terms, that means 39 purchases worth €3.8M on one side and 53 sales worth €4.9B on the other. The amount is not disclosed for 3 filings. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Since January 2026: no purchases and 2 sales on the market.
The median purchase comes to €27k. No cluster: in 38 purchases, no other insider of the company bought within 30 days.
The latest filing, published on 12 May 2026, reports a transaction of €1,969 in Novo Nordisk A/S. The last insider purchase was made public on 17 November 2025, 334 days ago. Filings reach the Finanstilsynet DK feed a median of 1 day after the trade. Under the Market Abuse Regulation, managers have three business days to notify their trades. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from Finanstilsynet DK. Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 114 declarations